Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505948 | 1.00 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6674621 | 0.88 | CA1 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6675273 | 0.87 | CA1 (0.36) | CA1CA2CA12CA7CA13 | |
| SCHEMBL25069061 | 0.82 | CA1 (0.31) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29671302 | 0.82 | CA1 (0.31) | CA1CA2CA12CA7CA13 | |
| SCHEMBL521623 | 0.81 | CA1 (0.50) | CA1CA2CA12CA7CA13 | |
| SCHEMBL31683748 | 0.78 | CA1 (0.45) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6680022 | 0.75 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL25358993 | 0.73 | CA1 (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL25359572 | 0.72 | CA1 (0.42) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| EP-1005453-B1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS | TULARIK INC (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1090014-B1 | ARYLSULFONANILIDE PHOSPHATES | TULARIK INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6417176-B2 | ANTICANCER AGENTS, PSORIASIS, RESTENOSIS, ATHEROSCLEROSIS | TULARIK, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6388131-B2 | Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) | TULARIK, INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | disclosed |
| US-6284923-B1 | BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS | TULARIK INC | 2001-09-04 | — | — | US | disclosed |
| US-20010018430-A1 | Arylsulfonanilide phosphates | TULARIK, INC. | 2001-08-30 | — | — | US | disclosed |
| EP-1090014-A1 | ARYLSULFONANILIDE PHOSPHATES | Tularik Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6211167-B1 | ANTICHOLESTEROL, ANTIPROLIFERATIVE AND ANTILIPEMIC AGENTS; CANCER, PSORIASIS, ATHEROSCLEROSIS, INFECTION AND VASCULAR RESTENOSIS TREATMENT | TULARIK INC. | 2001-04-03 | — | — | US | disclosed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999067258-A1 | ARYLSULFONANILIDE PHOSPHATES | TULARIK INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | CA1 4659/4885CA2 3895/4885CA12 4726/4885 |
| US-20010018430-A1 | Arylsulfonanilide phosphates | PIK3CA, INPP5D, INPPL1 | CA1 4626/4885CA2 3068/4885CA12 4574/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | CA1 4704/4885CA2 4486/4885CA12 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.